Modality
Multispecific
MOA
STINGag
Target
MET
Pathway
Notch
SLEAlzheimer's
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ May 2030
Phase 1Current
NCT08714879
373 pts·SLE
2024-07→2027-11·Not yet recruiting
NCT06879036
1,039 pts·Alzheimer's
2022-07→2030-05·Active
1,412 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-098mo awayEMA Filing· SLE
2027-11-211.6y awayPh2 Data· SLE
2030-05-174.1y awayPh2 Data· Alzheimer's
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Active
P1/2
Not yet…
Catalysts
EMA Filing
2026-12-09 · 8mo away
SLE
Ph2 Data
2027-11-21 · 1.6y away
SLE
Ph2 Data
2030-05-17 · 4.1y away
Alzheimer's
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08714879 | Phase 1/2 | SLE | Not yet recr... | 373 | LiverFat |
| NCT06879036 | Phase 1/2 | Alzheimer's | Active | 1039 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| Tezelucimab | Ascendis Pharma | Preclinical | SHP2 | |
| ASN-7408 | Ascendis Pharma | NDA/BLA | GPRC5D |